GlassScriptPhysician profile
Yu Hang Chen
NPI 1649879503
$2,972.27
in general payments reported to CMS, 2019-2025
9 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $481 · 2024: $1,182 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $716.34 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $611.62 | 2023-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $588.50 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Mallinckrodt Hospital Products INC. | $486.74 | 2023-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $256.20 | 2023-2025 | Cequa |
| Glaukos Corporation | $221.22 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $36.99 | 2024-2025 | Hydrus Microstent, Tryptyr |
| Harrow Eye, LLC | $28.26 | 2025 | Vevye |
| Astellas Pharma US INC | $26.40 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Hang Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.